Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma
暂无分享,去创建一个
Shinji Itoh | Shigeki Nakagawa | Yoshihiko Maehara | Hiromitsu Hayashi | Hideo Baba | Hideaki Uchiyama | Ken Shirabe | Y. Maehara | K. Shirabe | T. Ikegami | T. Yoshizumi | H. Baba | K. Imai | Y. Yamashita | S. Aishima | S. Nakagawa | H. Uchiyama | N. Harimoto | S. Itoh | T. Beppu | H. Okabe | Toru Ikegami | Tomoharu Yoshizumi | Shinichi Aishima | Katsunori Imai | Hirohisa Okabe | Yo-Ichi Yamashita | Norifumi Harimoto | Toru Beppu | H. Hayashi
[1] T. Han,et al. Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients , 2017, Hepatology.
[2] J. Zucman‐Rossi,et al. Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.
[3] M. Roncalli,et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. , 2014, Journal of hepatology.
[4] X. Wang,et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.
[5] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[6] M. Makuuchi,et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.
[7] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[8] A. Villanueva,et al. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. , 2016, Journal of hepatology.
[9] H. Honda,et al. Clinical usefulness of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.
[10] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[11] A. Belldegrun,et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial , 2017, JAMA oncology.
[12] Yan Lu,et al. Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells , 2016, Journal of cellular and molecular medicine.
[13] Masatoshi Kudo,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.
[14] J. Pastorek,et al. Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. , 2015, Seminars in cancer biology.
[15] Claudiu T. Supuran,et al. Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics , 2012, Oncotarget.
[16] K. Batts,et al. Prognostic Histologic Indicators of Curatively Resected Hepatocellular Carcinomas: A Multi-institutional Analysis of 425 Patients With Definition of a Histologic Prognostic Index , 2002, The American journal of surgical pathology.
[17] J. Habbema,et al. Prognostic Modeling with Logistic Regression Analysis , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.
[18] Bin Zhang,et al. Clinicopathological indices to predict hepatocellular carcinoma molecular classification , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[19] S. Hayami,et al. Triple Positive Tumor Markers for Hepatocellular Carcinoma Are Useful Predictors of Poor Survival , 2011, Annals of surgery.
[20] D. Zopf,et al. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.
[21] A. Belldegrun,et al. ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials. , 2013 .
[22] K. Jang,et al. Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma , 2015, Journal of pathology and translational medicine.
[23] G. Tiberio,et al. Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications , 2006, Annals of surgery.